WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site ...
Fierce Pharma

Recipharm channels ‘multi-million-dollar' US manufacturing upgrade, targeting domestic biologics demand

Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to ...
MarketWatch

MacroGenics to Sell Drug Making Operations to Bora Pharmaceuticals for $122.5M

MacroGenics, an antibody-based biopharmaceutical company, said Monday that pharmaceutical manufacturer Bora will assume responsibility for the manufacturing operations supporting clinical and ...
Fierce Biotech

For biopharma manufacturing at speed and scale, the future is flexible

Biopharma development has long trended toward specialized and personalized therapies such as cell and gene therapies, antibody-drug conjugates, and monoclonal antibodies (mAbs), among others. | ...
RAPS

Which Drug Manufacturing Changes Should be Reported? FDA Explains

New draft guidance issued by the US Food and Drug Administration (FDA) is intended to clarify which changes to a pharmaceutical company's manufacturing process must be reported to federal regulators, ...
FiercePharma

Starting material sourcing bottlenecks increase US drug shortage risks: report

USP noted that nearly half of the drugs included on its vulnerable medicine list have at least one of their key starting materials solely manufactured in one country, which the organization deemed a ...
Technology Networks

Beyond Pharma: How Bioprocessing Technologies Are Reshaping Food Production, Environmental Applications, and Sustainable Manufacturing

Discover how bioprocessing technology industrial applications expand as fermentation, membrane filtration, PAT, and ...